Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial

Osteoporosis International

Volumn 26, Issue 6, 2015, Pages 1857-1864

  Greenspan, S L ^a   Vujevich, K T ^a   Brufsky, A ^a   Lembersky, B C ^a   van Londen, G J ^a   Jankowitz, R C ^a   Puhalla, S L ^a   Rastogi, P ^a   Perera, S ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antiresorptives; Biochemical markers of bone turnover; Clinical trials; DXA

Indexed keywords

ANASTROZOLE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; EXEMESTANE; LETROZOLE; N TERMINAL PROPEPTIDE TYPE I PROCOLLAGEN; PLACEBO; PROCOLLAGEN C PROTEINASE; RISEDRONIC ACID; UNCLASSIFIED DRUG; VITAMIN D; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; BIOLOGICAL MARKER; BONE DENSITY CONSERVATION AGENT;

AGED; AMINO TERMINAL SEQUENCE; ARTICLE; BONE DENSITY; BONE MASS; BONE TURNOVER; BREAST CANCER; BREAST DISEASE; CALCIUM INTAKE; CANCER HORMONE THERAPY; CANCER SURVIVOR; CARDIOVASCULAR SYMPTOM; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HORMONE RECEPTOR POSITIVE BREAST CANCER; HUMAN; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MUSCULOSKELETAL DISEASE; OSTEOLYSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN CROSS LINKING; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; TREATMENT DURATION; VITAMIN SUPPLEMENTATION; BLOOD; BONE REMODELING; BREAST NEOPLASMS; CHEMICALLY INDUCED; DRUG EFFECTS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATHOPHYSIOLOGY;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BIOMARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RISEDRONATE SODIUM;

EID: 84931004851     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-015-3100-7     Document Type: Article

References (34)

1. Becker T, Lipscombe L, Narod S, Simmons C, Anderson GM, Rochon PA (2012) Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer. J Am Geriatr Soc 60(9):1761–1767. doi:10.1111/j.1532-5415.2012.04107.x
2. Bauer M, Bryce J, Hadji P (2012) Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer. Breast Cancer (Dove Medical Press) 4:91–101. doi:10.2147/bctt.s29432
3. Hadji P (2010) Guidelines for osteoprotection in breast cancer patients on an aromatase inhibitor. Breast Care (Basel, Switzerland) 5(5):290–296. doi:10.1159/000321426
4. Greenspan SL, Brufsky A, Lembersky BC, Bhattacharya R, Vujevich KT, Perera S et al (2008) Risedronate prevents bone loss in breast cancer survivors: a 2 year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol 26(16):2644–2652. doi:10.1200/JCO.2007.15.2967
5. Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C et al (2012) Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 118(5):1192–1201. doi:10.1002/cncr.26313
6. Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J et al (2012) Immediate Administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer 12(1):40–48. doi:10.1016/j.clbc.2011.08.002
7. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kassmann H, Piswanger-Solkner JC et al (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9(9):840–849. doi:10.1016/s1470-2045(08)70204-3
8. Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G et al (2010) Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 28(6):967–975. doi:10.1200/jco.2009.24.5902
9. Markopoulos C, Tzoracoleftherakis E, Koukouras D, Venizelos B, Zobolas V, Misitzis J et al (2012) Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. J Cancer Res Clin Oncol 138(9):1569–1577. doi:10.1007/s00432-012-1233-z
10. Van Poznak C (2010) Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition. Breast Cancer Res 12(3):110. doi:10.1186/bcr2584
11. Markopoulos C, Tzoracoleftherakis E, Polychronis A, Venizelos B, Dafni U, Xepapadakis G et al (2010) Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Breast Cancer Res 12(2):R24. doi:10.1186/bcr2565
12. Sestak I, Singh S, Cuzick J, Blake GM, Patel R, Gossiel F et al (2014) Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. Lancet Oncol 15(13):1460–1468. doi:10.1016/s1470-2045(14)71035-6
13. Sergi G, Pintore G, Falci C, Veronese N, Berton L, Perissinotto E et al (2012) Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer. J Bone Miner Metab 30(4):461–467. doi:10.1007/s00774-011-0341-1
14. Lester JE, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R et al (2008) Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 14(19):6336–6342. doi:10.1158/1078-0432.ccr-07-5101
15. Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S et al (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30(9):936–942. doi:10.1200/jco.2011.38.0261
16. Briot K, Tubiana-Hulin M, Bastit L, Kloos I, Roux C (2010) Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat 120(1):127–134. doi:10.1007/s10549-009-0692-7
17. Dawson-Hughes B, Jacques P, Shipp C (1987) Dietary calcium intake and bone loss from the spine in healthy postmenopausal women. Am J Clin Nutr 46:685–687
18. Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium; Ross AC, Taylor CL, Yaktine AL, Del Valle HB (eds) (2011) Dietary reference intakes for calcium and vitamin D. National Academies Press (US), Washington (DC)
19. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S et al (2014) Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int 25(10):2359–2381. doi:10.1007/s00198-014-2794-2
20. Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 4:368–381
21. Varney LF, Parker RA, Vincelette A, Greenspan SL (1999) Classification of osteoporosis and osteopenia in postmenopausal women is dependent on site-specific analysis. J Clin Densitom 2:275–283
22. Coleman RE, Banks LM, Girgis SI, Vrdoljak E, Fox J, Porter LS, et al (2005) Skeletal effect of exemestane in the Intergroup Exemestane Study (IES) 2 year bone mineral density (BMD) and bone biomarker data. Presented at 28th Annual San Antonio Breast Cancer Symposium
23. Howell A (2003) Effect of anastrozole on bone mineral density: 2-year results of the 'Arimidex' (anastrozole), Tamoxifen, Alone or in Combination (ATAC) trial. Presented at the San Antonio Breast Cancer Symposium 2003
24. Lonning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI et al (2005) Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23:5126–5137
25. Brufsky A, Harker W, Beck J, Carroll R, Tan-Chiu E, Seidler C, et al (2005) Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant Letrozole (Let): 12 mos BMD results of the Z-FAST trial. Presented at the annual meeting of the American Society of Clinical Oncology (ASCO)
26. Rubin DB (1987) Multiple imputation for nonresponse in surveys. John Wiley & Sons, Ltd., New York, NY
27. Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore HC et al (2009) Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 9(2):77–85. doi:10.3816/CBC.2009.n.015
28. Valachis A, Polyzos NP, Coleman RE, Gnant M, Eidtmann H, Brufsky AM et al (2013) Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist 18(4):353–361. doi:10.1634/theoncologist.2012-0261
29. Lonning PE, Eikesdal HP (2013) Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. Endocr Relat Cancer 20(4):R183–R201. doi:10.1530/erc-13-0099
30. Mathew A, Brufsky A (2014) Bisphosphonates in breast cancer. Int J Cancer. doi:10.1002/ijc.28965
31. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Fan M et al (2009) Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat 118(1):81–87. doi:10.1007/s10549-009-0352-y
32. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J et al (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26(30):4875–4882. doi:10.1200/jco.2008.16.3832
33. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB (1998) Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 13:1431–1438
34. Greenspan SL, Rosen HN, Parker RA (2000) Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab 85:3537–3540